IL-lIO was the only variable which differed
between the patients who developed polyarthritis, within three years and those without polyarthritis after this time, at 20.82(SD 8.79) v 4.19(4.73) pg mVl, P < 0.0001). A correlation was found between synovial fluid IL-1,B concentrations and the number of affected joints after three years (r = 0.739, P < 0.0001). Conclusions-Determination of synovial fluid IL-1f3 at disease onset may be useful in revealing the outcome of psoriatic monoarthritis since, among the variables considered in our study, this was the only one capable of predicting the evolution of monoarticular psoriatic arthritis to polyarthritis. (Ann Rheum Dis 1996; 55:642-644) Synovial fluid analysis represents one of the most important laboratory investigations for the diagnosis of arthritis. It has also been proposed that it can predict the outcome of rheumatoid arthritis' and juvenile chronic arthritis,2 both diseases characterised by subsets which differ in evolution and severity. Psoriatic arthritis has also been subdivided into subgroups according to its distribution and the number of joints involved.' Although the type of onset is thought to be important for the prediction of psoriatic arthritis outcome, the pattern of joint involvement frequently changes with time, in particular when it is monoarticular.4
As in other arthropathies, laboratory investigations in psoriatic arthritis may be useful in the early prediction of the type of evolution. Since psoriatic monoarthritis is frequently associated with large effusions, synovial fluid analysis may be considered in this context. Among inflammatory substances found in synovial fluid, increasing attention has recently been given to the cytokines.
Proinflammatory cytokines are thought to play a major role in chronic inflammation and joint destruction. Tumour necrosis factor (TNF) and interleukin (IL)-l stimulate the proliferation of synoviocytes and the secretion of cartilage and bone degrading enzymes.5 The synovial fluid concentrations of IL-15 have been found to be higher in psoriatic arthritis than in osteoarthritis and lower than in rheumatoid arthritis,6 thus suggesting a role for this cytokine in determining the type and severity of arthritis. Although results obtained in vitro suggest that cytokine measurement might have both diagnostic and prognostic value, until now very few reports have proposed in vivo synovial fluid cytokine measurement for the prediction of disease outcome.7
The aim of this study was to investigate the value of synovial fluid analysis in predicting the outcome of monoarticular psoriatic arthritis.
Methods
We examined the synovial fluid of 18 patients (10 female and eight male, mean age 47.1 years, range 18 to 60) with monoarticular onset of psoriatic arthropathy. Patients were required to satisfy the criteria of Moll and Wright for the diagnosis of psoriatic arthritis' and to have had a disease duration of less than six months. The majority of patients (10/18 = 55.5%) were taking non-steroidal antiinflammatory drugs (NSAIDs). None of the patients had received any intra-articular or systemic steroid or slow acting antirheumatic drugs (SAARDs) before the study.
Patients were first observed for six months and then monitored for a period of at least three years (range 36 to 40 months) to define the type of outcome. Only patients whose disease remained monoarticular in the first six months after onset were accepted. After three years, patients were subdivided, according to disease evolution, into a group with polyarthritis (five or more joints affected) and a group without polyarthritis (four or fewer joints affected).
Synovial fluid was aspirated from knee joints to dryness. Two millilitres of fluid from the knee were collected into lithium heparin for white blood cell count (WBC). The remaining synovial fluid was centrifuged at 3000 rpm for 10 min and the supernatant was stored at -20°C in multiple small volumes. Total protein was measured by Biuret's method and IL-i1 was determined using a commercially available sensitive and specific enzyme linked immunoasorbent assay (ELISA)(RD Systems; limit of detection 0.3 pg ml-'). Acid phosphatase and lysozyme activities were measured using colorimetric methods. Paired blood samples were collected for determination of erythrocyte sedimentation rate (ESR, Westergren method) and serum C reactive protein (nephelometry). No patient had rheumatoid factor (nephelometry) 
